GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Akoya Biosciences Inc (NAS:AKYA) » Definitions » Selling, General, & Admin. Expense

Akoya Biosciences (Akoya Biosciences) Selling, General, & Admin. Expense : $80.49 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Akoya Biosciences Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Akoya Biosciences's selling, general, & admin. expense for the three months ended in Mar. 2024 was $19.86 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2024 was $80.49 Mil.


Akoya Biosciences Selling, General, & Admin. Expense Historical Data

The historical data trend for Akoya Biosciences's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akoya Biosciences Selling, General, & Admin. Expense Chart

Akoya Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Selling, General, & Admin. Expense
26.35 23.98 51.02 79.65 82.38

Akoya Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.12 22.71 19.02 18.90 19.86

Competitive Comparison of Akoya Biosciences's Selling, General, & Admin. Expense

For the Medical Instruments & Supplies subindustry, Akoya Biosciences's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akoya Biosciences's Selling, General, & Admin. Expense Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Akoya Biosciences's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Akoya Biosciences's Selling, General, & Admin. Expense falls into.



Akoya Biosciences Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $80.49 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Akoya Biosciences  (NAS:AKYA) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Akoya Biosciences Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Akoya Biosciences's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Akoya Biosciences (Akoya Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
100 Campus Drive, 6th Floor, Marlborough, MA, USA, 01752
Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery and clinical research. The company offers the comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications. The company has its geographical presence in North America, APAC and EMEA. It generates majority of the revenue from North America.
Executives
Brian Mckelligon director, officer: President/CEO 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752
Frederic Pla officer: Chief Operating Officer C/O GENOMIC HEALTH, INC., 101 GALVESTON DRIVE, REDWOOD CITY CA 94063-4700
Goldman Myla Lai director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
John Frederick Ek officer: Chief Financial Officer 5964 LA PLACE COURT, CARLSBAD CA 92008
Scott Mendel director 5964 LA PLACE COURT, ADDRESS 2, CARLSBAD CA 92008
Matthew Winkler director C/O MIRNA THERAPEUTICS, INC., 2150 WOODWARD ST., SUITE 100, AUSTIN TX 78744
Thomas A. Raffin director, 10 percent owner C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AIMES IA 50010
Robert G Shepler director
Jennifer Kamocsay officer: General Counsel 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01762
Joseph Driscoll officer: Chief Financial Officer 5 DICARLO ROAD, HOPKINTON MA 01748
Nolan Garry Ph.d. director 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752
Thomas P Schnettler director 800 NICOLLET MALL, J1012057, MINNEAPOLIS MN 55402-7020
Ehab El-gabry officer: Chief Medical Officer 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752
Marilee Moy officer: Chief People Officer 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752
Ramachandran Niro Ph.d officer: Chief Business Officer 100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752

Akoya Biosciences (Akoya Biosciences) Headlines

From GuruFocus

Akoya Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2022

By Stock market mentor Stock market mentor 01-08-2023